Highlights

  • NEU shares climbed 7.51% to AUD 20.75 on 14 Jan 2026.
  • Acadia projects global DAYBUE net sales of ~USD 700m by 2028.
  • Over 2,000 Rett syndrome patients have been treated with DAYBUE since US launch.

Neuren Pharmaceuticals (ASX:NEU) saw its shares trade at AUD 20.75 on 14 January 2026, up 7.51% for the day. The company has recorded a 7.62% increase over the past month, a 44.43% rise in the last six months, and an 11.66% gain year-to-date.

DAYBUE Global Sales Outlook
Neuren’s partner, Acadia Pharmaceuticals, presented updates at the J.P. Morgan Healthcare Conference, outlining projections for DAYBUE® net sales to reach approximately USD 700m by 2028. This forecast reflects continued patient adoption, new formulations, and expansion into international markets.

Since its US launch in 2023, more than 2,000 patients with Rett syndrome have received DAYBUE treatment. Twelve-month treatment persistency has increased to 55%, indicating ongoing adherence among patients.

The recently FDA-approved DAYBUE STIX powder formulation is expected to launch in the US in Q1 2026, with full availability projected by Q2. This new formulation could influence patient uptake in the US market.

International Progress and Trials
International developments include approval of DAYBUE oral solution in Israel, while European regulatory review is continuing. In Japan, a Phase 3 trial of trofinetide is ongoing, with top-line results anticipated in late 2026 or early 2027. These developments highlight the company’s ongoing efforts to expand access to DAYBUE across multiple markets.

Key Points Summary
Neuren Pharmaceuticals’ stock performance on ASX reflects market attention to updates on DAYBUE. The company’s progress includes new formulations, patient adoption rates, and ongoing international regulatory and clinical activities.